The added benefit of glucagon in artificial pancreas systems for overnight glucose control in type 1 diabetes has not been fully explored.
Although current research initiatives are exploring novel strategies for improving glycemic control (3) , such as adjunctive-to-insulin pharmacotherapies, immunomodulation, and cell-based therapies to maintain or recover insulin-producing beta cell mass, the standard of care remains intensive insulin therapy (4, 5) .
As an alternative to multiple daily injections, intensive insulin therapy in the current era of type 1 diabetes management is frequently delivered by insulin pump and may be accompanied by continuous glucose monitoring (CGM) (6) . Commercially available sensor-augmented pump therapy that integrates pump with interstitial CGM has demonstrated substantial improvement in glycemic control compared with multiple daily injection therapy (7, 8) . A configuration that makes use of simple thresholdbased insulin interruption in the face of hypoglycemia has also been shown in large randomized controlled studies to decrease, but not eliminate, risk in those at intermediate and high risk of hypoglycemia (9, 10) . Research is under steady progress to develop automated external artificial pancreas systems that incorporate more sophisticated dosing algorithms. To date, two configurations have been developed: one that infuses insulin and another that infuses insulin and glucagon. In short-term studies, both have demonstrated greater efficacy for the intermediate outcome of time-in-target glucose and have frequently reported a decrease in hypoglycemia compared with conventional insulin pump therapy (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . Although benefits of the dual-hormone configuration have been demonstrated in a nonrandomized trial (17) , in controlled inpatient settings (16, 18) , and in a 5-day outpatient randomized trial against conventional pump therapy (20) , there currently exists insufficient knowledge of the additional benefits of glucagon compared with the insulinalone strategy. We recently showed favorable trends for glucagon over the insulin-alone configuration in a 24hour inpatient setting (24) and an overnight camp setting (25) , but there remains a need for further systematic headto-head comparisons in the home setting. Knowledge of this incremental benefit is of critical importance because this dual-hormone configuration raises system complexity and costs (26) .
As a step beyond previous head-to-head inpatient and camp studies (18, 24, 25) , we aimed to compare at home in a randomized, multicenter crossover study of adults and adolescents with type 1 diabetes the efficacy of single-hormone artificial pancreas, dual-hormone artificial pancreas, and conventional insulin pump therapy on the overnight proportion of time-in-target glycemia using stimuli to induce hypo-and hyperglycemic excursions.
Research Design and Methods

Study design and participants
We used an open-label, randomized, three-arm, crossover trial, applied over 6 study nights, to compare each of the three interventions: the dual-hormone (insulin and glucagon) artificial pancreas, the single-hormone (insulin alone) artificial pancreas, and conventional insulin pump therapy. Each participant completed 2 nights on each of the three interventions, with intervention sequence randomly assigned. The first study night was preceded by a high-carbohydrate/high-fat meal, and the second was preceded by exercise. Each study night was conducted in an outpatient setting at the participant's home.
From September 2013 to October 2014, adults aged 18 years or older and adolescents aged 12-17 years with at least 1-year duration type 1 diabetes and 4-month duration pump therapy were recruited from three Canadian clinical centers: the Institut de Recherches Cliniques de Montréal, the Montréal Children's Hospital, and Mount Sinai Hospital in Toronto, Canada. All participants provided written informed consent, and the ethics board of each site approved the study. Full inclusion and exclusion criteria are given in the Supplemental Material.
Randomization and masking
We used blocked randomization with an equal (1:1:1:1:1:1) allocation ratio to the six possible intervention sequences. Participants and investigators were not masked to allocation or to fingerstick glucose measurements during conventional insulin pump therapy, but participants were masked to fingerstick and sensor glucose levels and to hormone infusions during artificial pancreas visits.
Interventions and procedures
Participants completed an admission visit during which history, physical, and laboratory examinations were conducted. Insulin aspart (Novorapid; Novo Nordisk), a Paradigm Veo insulin pump, Enlite electrochemical sensors, a Sen-serter insertion device, a MiniLink radiofrequency transmitter (Medtronic Canada, Inc), and detailed technical training were provided. System calibration used fingerstick glucose (Bayer Contour Link; Bayer Diagnostics Canada), and infusion site, insulin reservoir, and electrochemical sensor changes were made 1 day prior to each intervention arm. The same sensor was used for the 2 nights of each intervention, without replacement in the event of suspected suboptimal accuracy. To ensure conventional therapy optimization, data were reviewed by investigators 3-5 days after the admission visit. Specifically, basal and bolus delivery parameters were adjusted if fasting glucose was outside 4 -9 mmol/L in 2 of 3 mornings. During the dual-and single-hormone interventions, sensor glucose levels were manually entered every 10 minutes into an on-site laptop computer running the control (dosing) algorithm. The recommended variable insulin infusion rates and glucagon microdoses via a second pump were then manually programmed to regulate glucose levels. In contrast, during conventional insulin pump therapy, participants freely implemented their usual basal rate and boluses to regulate glucose levels, and sensor glucose was recorded every 10 minutes by study staff. Each intervention was conducted at the participant's home. Staff arrived at 8:30 PM to operate the algorithm from 9:00 PM to 7:00 AM and ensure protocol implementation and safety. Insulin delivery algorithms were identical in both the single-hormone and the dual-hormone artificial pancreas systems except that glucagon on board was taken into account by the insulin delivery algorithm of the dual-hormone artificial pancreas. A description of the control algorithm is given in the Supplemental Material.
To mimic glycemic excursions, each intervention arm was conducted during 2 nights: the first was a high-carbohydrate/ high-fat meal night and the second was an exercise night. For the meal night, the dinner meal was replaced by a standardized meal (110 g carbohydrates [CHO], 41.8 g fat, 35.2 g protein, and 949.7 kcal for males; 90 g CHO, 35 .5 g fat, 29.3 g protein, and 789.5 kcal for females). The meal was delivered to the participants' homes, eaten at 7:30 PM, and participants were instructed to subsequently fast and to avoid alcohol and further exercise. For the exercise night, study participants performed an exercise routine at 6:00 PM, prescribed but not directly supervised by staff. Adults performed 60 minutes of exercise at 60% heart rate reserve, whereas adolescents performed 60 minutes of exercise to a target heart rate of 140 beats per minute (27) . The workout included either treadmill running or stationary bicycling for an hour or 30 minutes of each. The exercise pattern as well as a standardized meal selected from a menu (67-71 g CHO, 15.75-17.7 g fat, 22-34.7 g protein, 445-567 kcal, in which the ranges reflect vegetarian and nonvegetarian options) were repeated on the subsequent exercise nights. On these nights, participants had the option of an extra bedtime snack that, if chosen, was repeated on all exercise nights.
At night, hypoglycemia surveillance was managed as follows: 1) in the event of sensor glucose level less than 3.7 mmol/L, HemoCue capillary glucose (HemoCue AB) was determined by the coordinator; if the HemoCue glucose level was less than 3.0 mmol/L, 15 g oral carbohydrates was given; and 2) if the patient was symptomatic, the HemoCue glucose level was checked; if the HemoCue glucose level was less than 3.3 mmol/L, 15 g oral carbohydrates was given. The occurrence of either of these two events was defined as an Incident of hypoglycemia requiring treatment. For hyperglycemia surveillance, if the sensor glucose level was greater than 18.0 mmol/L and confirmed by HemoCue, the participants were asked to use their pump's bolus wizard to deliver a correction bolus. Participants were blinded to sensor and HemoCue glucose values during artificial pancreas study nights. HemoCue values, used in surveillance for safety, were not used in the data analysis, and the same surveillance procedures were applied during all interventions.
End points
All end points were calculated for the period from 11:00 PM to 7:00 AM, and data from the 2 nights (high carbohydrate/high fat and exercise nights) were pooled together for analyses. The primary end point was the percentage of time for which sensor glucose levels were within 4.0 -8.0 mmol/L, inclusive.
Statistical analysis
Statistical analysis was performed using SAS 9.2 (SAS Institute). Categorical variables were reported as frequency (percentage), whereas continuous variables were reported as mean (SD) or median (interquartile range [IQR]). Continuous variables were assessed for normality (Shapiro-Wilk). For continuous outcome variables, the intervention effect was assessed using a linear mixed-effects model (LMEM), with participant as random effect and intervention and intervention sequence as fixed effects. To meet LMEM assumptions, nonnormal variables were transformed using log or square root. The effect of intervention on discrete variables was assessed using a generalized estimating equation with the same random and fixed-effect variables. An ␣-level of .05 was used to determine statistical significance. All participants completed each planned study night, but eight participants experienced at least one missing CGM sensor reading (of 97 possible values per participant from 11:00 PM to 7:00 AM inclusive in 5 minute increments), handled by imputation using linear interpolation (24) . Additional details of missing data and sample size are included in the Supplemental Material. A model using negative-binomial regression on untransformed variables with the same random and fixed-effects structure was used as a sensitivity analysis to address potential overdispersion.
Role of funding source
The study was funded by the Canadian Diabetes Association and the J-A DeSève Foundation, and in-kind material support was provided by Medtronic Inc. None of these played a role in study design, data collection, or analysis.
Results
Forty-three patients were approached and assessed for eligibility, and 28 (65%) were randomized ( Figure 1 ). All 28 randomized participants completed the 6 nights of the protocol. Mean age was 33 (standard deviation [SD] 17) years, with 18 (SD 12) years diabetes duration, mean total daily insulin of 0.66 (SD 0.24) U/kg, mean body mass index (BMI) of 24.9 (SD 3.8) kg/m 2 , baseline glycated hemoglobin (HbA1c) of 7.5% (SD 1.0%), and 15 (54%) were female, as shown in Table 1 . Characteristics are also shown according to adult and adolescent age groups.
Overnight sensor glucose profiles obtained during each intervention for the 28 participants are summarized in Figure 2 , top row. Qualitatively, although the IQRs appear similar at the beginning of the study periods, they become lower and narrower as the study nights progressed for the artificial pancreas configurations compared with conventional insulin pump therapy. Percentage of timein-target 4 -8 mmol/L of overnight sensor glucose readings, presented in the first section of Table 2 and expressed as median (IQR) were 47% (36%, 71%) during conven-tional pump therapy, 76% (65%, 91%) during singlehormone, and 81% (68%, 93%) during dual-hormone artificial pancreas. Compared with conventional therapy, this corresponded to a higher time in target of 30% (Ϫ4%, 46%), which corresponds to an additional 2.4 hours during the night, during single-hormone therapy (HT), and 27% (13%, 42%), or 2.2 additional hours, during dual HT (P Ͻ .001 for both comparisons). There was no doi: 10.1210/jc.2015-3003 press.endocrine.org/journal/jcem observed difference in time in target between single-and dual-hormone therapies (P ϭ .50). A similar pattern was observed when the target was set to 4 -10 mmol/L ( Table 2) . Shown in Table 2 , the median percentage of time of sensor glucose readings less than 4.0 mmol/L was 14% (4%, 28%) during conventional pump therapy, 5% (0%, 13%) during single HT, and 1% (0%, 8%) during dual HT. Compared with conventional therapy, this corresponded to a lower time spent less than 4.0 mmol/L of 6% (Ϫ15%, 0%), corresponding to 29 fewer minutes during single HT, and 7% (24%, Ϫ1%), corresponding to 34 fewer minutes, during dual HT (P ϭ .004 and P Ͻ .001, respectively). The median difference in time spent less than 4.0 mmol/L between dual and single hormone was 0% (Ϫ6%, 5%) (P ϭ .34). Similar observations were found for time spent less than 3.5 mmol/L and less than 3.3 mmol/L ( Table 2 ). The second row of Figure 2 shows the distribution of hypoglycemia according to sensor values over time during the study nights. Both artificial pancreas configurations demonstrate a substantial reduction in hypoglycemia, particularly in the latter half of the night. The Figure 2 . Profile of glucose levels, percentage of nights in hypoglycemia with incidents requiring treatment indicated, and percentage of nights in hyperglycemia for the 28 participants with type 1 diabetes according to intervention. The blue lines represent the dual-hormone artificial pancreas, red lines represent the single-hormone artificial pancreas, and the black lines represent conventional insulin pump therapy. In the top row, the solid lines represent median sensor glucose, and the shaded areas correspond to the indicated errors (IQR in the left panel and 10th to 90th percentile in the right panel). The shaded blue area corresponds to the dual-hormone artificial pancreas, the shaded red area corresponds to the single-hormone artificial pancreas, and the shaded gray area corresponds to conventional insulin pump therapy. The second and third rows show, at each time point between 11:00 PM and 7:00 AM, the percentage of nights at each time point spent below or above the indicated thresholds. In the second row left panel, the dots represent incidents of hypoglycemia requiring treatment according to each intervention arm.
incidence and timing of hypoglycemia requiring treatment are indicated by blue, red, and black dots and reveal a similar pattern of marked reduction particularly in the latter half of the night. In total, there were 14 incidents of hypoglycemia requiring treatment during conventional pump therapy, six incidents during single hormone (P ϭ .059 for comparison with conventional), and three incidents during dual HT (P ϭ .017 for comparison with conventional and P ϭ .42 for comparison with single hormone, shown in Table 2 ). The median time of occurrence of hypoglycemia requiring treatment was 12:17 AM (11:22 PM, 2:10 AM) on conventional therapy, 1:35 AM (12:00 AM, 2:50 AM) on single HT, and 1:43 AM (11:20 PM, 2:05 AM) on dual HT. The number of participants experiencing at least one incident of hypoglycemia requiring treatment did not differ between each therapy (P ϭ .115 for conventional and single hormone, P ϭ .073 for conventional and dual hormone, and P ϭ .74 for single hormone and dual hormone comparisons, Table 2 ). Representing intensity and duration of hypoglycemia by the area under the curve (AUC) for sensor values at the three predefined hypoglycemia thresholds yielded the same pattern of findings as the time-in-target variables.
Time spent in hyperglycemia above 8 mmol/L (and 10 mmol/L) was significantly lower during both single and dual HTs when compared with conventional therapy but was not different between the single-and dual-hormone configurations ( Table 2 ). Figure 2 , bottom row, displays the percentage of nights spent in hyperglycemia as measured by sensor glucose. On conventional therapy, hyperglycemia tended to increase as the night progressed, whereas on single-and dual-hormone interventions, hyperglycemia tended to decrease. The AUC for sensor values above 8 and 10 mmol/L were significantly lower for the single-hormone configuration compared with conventional pump therapy but not for the other comparisons ( Table 2) .
Mean sensor glucose readings were low and not different between interventions: 6.7 mmol/L (5.8, 7.8 mmol/L) during conventional pump therapy, 6.2 mmol/L (5.8, 6.8 mmol/L) during single HT, and 6.2 mmol/L (5.8, 7.0) mmol/L during dual HT (P ϭ .29, Table 2 ).
Basal insulin delivery, shown in Figure 3 , top row, was relatively stable during conventional pump therapy and was much more variable, particularly earlier in the night, during single-and dual-hormone therapies. The total amount of insulin delivered overnight did not differ between any of the three therapies ( Table 3 ). The amount of insulin delivered in the 2 hours preceding incidents of hypoglycemia during single-and dual-hormone intervention Data are presented as median (IQR) unless indicated otherwise. Percentage of time spent at indicated glucose levels, AUC, and glucose variability parameters are all based on sensor glucose readings taken from 11:00 PM to 7:00 AM, and data presented combine the 2 nights for each intervention. Differences expressed as median (IQR) do not necessarily reflect the differences of the medians. a According to the surveillance protocol, these hypoglycemia events represented those confirmed as less than 3.0 mmol/L by Hemocue or less than 3.3 mmol/L with hypoglycemic symptoms. doi: 10.1210/jc.2015-3003 press.endocrine.org/journal/jcem nights was 22% (15%, 45%) and 11% (0%, 82%) of the insulin delivered during conventional pump therapy nights during the same period, respectively. For the dualhormone intervention, the median amount of nightly glucagon delivered was 0.026 mg (0.016, 0.117 mg), which amounted to 0.4 g/kg (0.2, 1.5 g/kg) standardized by body weight (Figure 3 , bottom row). Glucagon dose did not differ between the high-carbohydrate/high-fat night and the exercise night (0.4 g/kg [0.0,1.5 g/kg] vs 0.4 g/kg (0.1, 1.4 g/kg], P ϭ .75). Twenty-seven percent of all glucagon was delivered before 1:00 AM, 57% was delivered before 3:00 AM, and 79% was delivered before 5:00 AM. No participant reported any gastrointestinal symptoms after the glucagon administration. The num- Data are presented as median (IQR), unless indicated otherwise. Insulin delivery, glucagon delivery, and carbohydrate intake are taken from 11:00 PM to 7:00 AM. For insulin delivery and glucagon delivery, the results from both the high-carbohydrate/high-fat meal night and the exercise night were averaged (rather than combined) to produce nightly totals. a P ϭ .75 for meal/exercise comparison (Wilcoxon signed rank test). Median difference was 0 (Ϫ0.5, 0.4) g/kg. Total carbohydrate intake (in grams) represented ingestion required for hypoglycemia treatments, snacks, and early breakfasts. The additional carbohydrate intake observed in the hours after 11:00 PM for conventional therapy was explained by the greater incidence of hypoglycemia (as shown in the second row left panel of Figure 2 ). Snacks were standardized for all arms and allowed only on exercise nights. At 6:30 AM, there were multiple instances of carbohydrate ingestion owing to early breakfast: there were seven such events totaling 382 g on conventional pump therapy, five events totaling 271 g on single-hormone, and five events totaling 253g on dual-hormone artificial pancreas. These instances of early breakfast carbohydrate intake are indicated by an asterisk in the plots above. Based on the observation of this early breakfast prior to 7:00 AM in a subset of participants, we performed a post hoc sensitivity analysis restricting data to the sensor values that preceded the early breakfast carbohydrate intake. The results of this sensitivity analysis did not differ from the results of the primary analysis. Glucagon delivery is shown as the sum of milligrams administered across high-carbohydrate/high-fat and exercise nights.
ber of participants ingesting carbohydrates from 11:00 PM through 7:00 AM did not differ across each therapy (Table 3) . Data stratified by night (high carbohydrate/high fat compared with exercise nights) showed similar trends to pooled analysis (Supplemental Tables 1 and 2) . A sensitivity analysis restricting data to the sensor values that preceded the early-breakfast carbohydrate intake prior to 7:00 AM demonstrated results similar to the primary analysis (detailed in Figure 3, legend) . The effect of intervention sequence was insignificant and results of the negativebinomial, mixed-effects model did not differ from the LMEM results described.
Discussion
In this head-to-head at-home comparison of the efficacy of single-and dual-hormone artificial pancreas configurations on overnight glycemic control in patients with type 1 diabetes, both configurations improved the amount of time spent in target glycemic range and improved other measures of hyper-and hypoglycemic exposure when compared with conventional insulin pump therapy in the setting of stimuli designed to increase overnight glycemic excursions. However, this study failed to demonstrate a significant advantage of the dual-hormone strategy as compared with the single-hormone strategy for overnight glycemic control, even in the setting of an antecedent highcarbohydrate/high-fat meal or exercise, although we cannot rule out a lesser effect on hypoglycemia risk, as observed by a trend in the lowest hypoglycemia incidence occurring with the dual-hormone configuration.
Ultimately the determination of the efficacy of artificial pancreas technologies in glycemic management will arise from long-term randomized controlled trials implemented in free-living outpatient settings designed to evaluate HbA1c and hypoglycemic risk as the primary outcomes of interest. Although the development of the artificial pancreas continues to rely on short-term studies designed to evaluate the effect on time-in-target glycemia from CGM major headway has been made. For the dual-hormone artificial pancreas, a recent report of two outpatient, randomized, controlled, cross-over studies demonstrated that better glycemic control could be achieved with the dualhormone configuration compared with conventional pump therapy over 5 days (20) . Among adults and adolescents in those studies, after a 1-day artificial pancreas adaptive learning phase, the percentage of time spent between 4 and 10 mmol/L during the night was higher with the dual-hormone strategy, similar in magnitude to our findings. Also consistent with our findings, the overnight percentage of time in the hypoglycemic range was reduced, although this could not be demonstrated in the adolescent subgroup (20) . These comparable findings existed despite differences in the doses of glucagon delivered, which were substantially higher than those used in the approach implemented in the current study (20) . For the single-hormone artificial pancreas, longer-term outpatient overnight studies were conducted by independent groups in adolescent and adult patients over 3-6 weeks (12, 15, 19, 28) , and recently these outpatient studies have been extended to 3 months (23). The investigators also observed a greater percentage of time spent between 4 and 8 mmol/L compared with sensor-augmented pump therapy, but the magnitude of improved time in target was greater in the current study, likely owing to differences in the comparator groups (conventional pump therapy vs sensor augmented pump therapy) and the shorter duration of our study.
Although the results of the previously published dualhormone and single-hormone strategies made major contribution to our understanding of the efficacy of artificial pancreas systems, we cannot determine from their designs the necessity of incorporating glucagon (11-15, 17-20, 29 -31) . In the setting of a controlled inpatient setting counterbalanced by large and small meals as well as exercise, we previously compared both artificial pancreas configurations with conventional therapy on 24-hour glycemic excursions in adults and adolescents (24) . In that study, the mean proportion of time in target over 24 hours was 62% (SD 18%), 63% (SD 18%), and 51% (SD 19%) with single-and dual-hormone artificial pancreas and conventional insulin pump therapy, respectively. Although we could not discern a glycemic benefit between the two artificial pancreas systems during the overnight hours, the study raised the hypothesis that the contribution of glucagon may be required primarily in the prevention of postprandial glycemic excursions (24) .
Taken together with previous work, the results of the current study confirm in a more clinically generalizable outpatient setting the finding that a single-hormone artificial pancreas strategy may be sufficient for overnight glycemic control. However, we cannot rule out the potential benefit of glucagon for overnight glycemic control in certain situations such as hypoglycemia unawareness, after inaccurate dosing of the evening meal insulin bolus, and prolonged exercise as observed, for example, in diabetes camp settings. In a recent study that we conducted in a diabetes camp (25) , adding glucagon to the artificial pancreas led to additional benefits overnight and to reduction of nocturnal hypoglycemia compared with the single-hormone artificial pancreas. This difference compared with the current study may be related to differences in settings (extreme camp vs home), population (children and adolescents vs adolescents and adults), sensor (Dex-doi: 10.1210/jc.2015-3003 press.endocrine.org/journal/jcem com G4 vs Medtronic Enlite), or prenight events (complete free living with antecedent snack vs antecedent high carbohydrate/high fat meal or exercise followed by a meal). Longer and larger studies are still needed. Despite major advantages by virtue of the outpatient setting, inclusion of stimuli to induce glycemic excursion (27, (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) , and the head-to-head comparison design, the current study has limitations. First, the short duration of exposure (2 nights per intervention) limits the power to detect glycemic outcomes and requires future longer-term studies. Second, although conducted in patients' homes, the presence of a study coordinator for safety monitoring introduces a nondifferential surveillance bias that may also limit power by attenuating outcomes. Although we introduced as a countermeasure to these limitations the stimuli for glycemic excursions, the study was not powered to detect differences in hypoglycemia incidence; as such, the 50% nonsignificantly lower incidence observed in the dual-hormone phase compared with the single-hormone configuration may in the future be found to be of relevance. Fourth, we used manual control rather than a fully automated system, but that resulted in robust data transmission and avoided the technical problems reported by others (12, 20, 31) and therefore reflects performance of a future error-free automated transmission system. Finally, this study was not designed to define the role of glucagon for daytime glycemic control. Future work must move beyond proxy measures of glycemic control and, in parallel with studies of the safety of microdose glucagon and human factors, operationalize feasible systems that can be implemented in longer protocols to evaluate the most clinically relevant outcomes: HbA1c and severe hypoglycemia incidence.
